News and Announcements
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) receives $2.2 million R&D cash rebate
- Published February 11, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Australian oncology-focused biotechnology company, Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) has received a $2.2 million R&D cash rebate.
The ASX listed company is pleased to confirm they received $2,191,257.95 from the Australian Taxation Office under the R&D tax Incentive Program for the financial year ending 30 June 2018.
Kazia CEO, Dr James Garner, said: ““The R&D tax rebate is an important, non-dilutive source of funding for the Company.”
“The amount is consistent with the expectations laid out in our financial reports, and the funds will be invested in progressing our two clinical programs.”
“This is an important year for Kazia, with multiple data read-outs anticipated in the near future.”
About Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA)
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is developing cancer treatments for areas which there is a high unmet medical need. Our lead program, GDC-0084, a drug to treat glioblastoma multiforme, the most aggressive brain cancer, has completed phase 1 human trials with strong safety and early efficacy signals. It is currently being prepared for phase 2 human trials.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
